CHRISTOPHER JOHN KENNEY, the Chief Medical Officer of $XENE, sold 1,410 shares of the company on 03-13-2026 for an estimated $77,867. We received data on the trade from a recent SEC filing. This was a sale of approximately 16.6% of their shares of this class of stock. Following this trade, they now own 7,069 shares of this class of $XENE stock.
$XENE Insider Trading Activity
$XENE insiders have traded $XENE stock on the open market 22 times in the past 6 months. Of those trades, 0 have been purchases and 22 have been sales.
Here’s a breakdown of recent trading of $XENE stock by insiders over the last 6 months:
- IAN MORTIMER (PRESIDENT & CEO) has made 0 purchases and 18 sales selling 378,879 shares for an estimated $21,298,055.
- CHRISTOPHER JOHN KENNEY (Chief Medical Officer) has made 0 purchases and 2 sales selling 4,181 shares for an estimated $244,426.
- ANDREA DIFABIO (Chief Legal Officer) has made 0 purchases and 2 sales selling 3,949 shares for an estimated $230,813.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XENE Hedge Fund Activity
We have seen 127 institutional investors add shares of $XENE stock to their portfolio, and 113 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BRAIDWELL LP removed 1,779,953 shares (-49.4%) from their portfolio in Q4 2025, for an estimated $79,777,493
- WELLINGTON MANAGEMENT GROUP LLP added 1,154,922 shares (+32.0%) to their portfolio in Q4 2025, for an estimated $51,763,604
- COMMODORE CAPITAL LP removed 900,000 shares (-33.3%) from their portfolio in Q4 2025, for an estimated $40,338,000
- DEEP TRACK CAPITAL, LP removed 833,565 shares (-69.5%) from their portfolio in Q4 2025, for an estimated $37,360,383
- PRICE T ROWE ASSOCIATES INC /MD/ added 820,608 shares (+1968.3%) to their portfolio in Q4 2025, for an estimated $36,779,650
- MILLENNIUM MANAGEMENT LLC removed 748,951 shares (-54.1%) from their portfolio in Q4 2025, for an estimated $33,567,983
- HOLOCENE ADVISORS, LP removed 694,472 shares (-35.1%) from their portfolio in Q4 2025, for an estimated $31,126,235
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XENE Analyst Ratings
Wall Street analysts have issued reports on $XENE in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/18/2025
- Needham issued a "Buy" rating on 11/04/2025
- RBC Capital issued a "Outperform" rating on 11/04/2025
- Chardan Capital issued a "Buy" rating on 10/07/2025
To track analyst ratings and price targets for $XENE, check out Quiver Quantitative's $XENE forecast page.
$XENE Price Targets
Multiple analysts have issued price targets for $XENE recently. We have seen 10 analysts offer price targets for $XENE in the last 6 months, with a median target of $66.0.
Here are some recent targets:
- David Hoang from Deutsche Bank set a target price of $90.0 on 03/10/2026
- Douglas Tsao from HC Wainwright & Co. set a target price of $74.0 on 03/10/2026
- Laura Chico from Wedbush set a target price of $64.0 on 03/10/2026
- Benjamin Burnett from Wells Fargo set a target price of $68.0 on 03/10/2026
- Serge Belanger from Needham set a target price of $80.0 on 03/09/2026
- Brian Skorney from Baird set a target price of $97.0 on 03/09/2026
- Rudy Li from Wolfe Research set a target price of $60.0 on 02/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
